Birch pollen allergy vaccine tablet - ALK-Abello

Drug Profile

Birch pollen allergy vaccine tablet - ALK-Abello

Alternative Names: ALK Tree Tablet; Betula Verrucosa allergen extract; Oralgen Birch Pollen; SLIT birch pollen extract; SLITone Birch; SLITonePLUS Birch

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 18 Mar 2016 Phase-III clinical trials in Allergic rhinoconjunctivitis (In adolescents, In adults) in Sweden (Sublingual) (EudraCT2015-004821-15)
  • 26 Aug 2015 Phase-II development for Allergic rhinoconjunctivitis is ongoing in Europe
  • 08 Nov 2013 ALK-Abelló completes a phase II trial in Allergic rhinoconjunctivitis (In adolescents, In adults) in Denmark and Finland (NCT01675791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top